SCHEMBL23214480

SCHEMBL23214480

COC(=O)c1ccc(C(C)NC(=O)C(O)C(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
CA12 O43570 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
CA7 P43166 1/20 0.44
ALDH1A1 P00352 4/20 0.44
MAPT P10636 4/20 0.44
LMNA P02545 2/20 0.44
MITF O75030 1/20 0.44
TP53 P04637 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
PDE2A O00408 1/20 0.43
TSHR P16473 1/20 0.42
PTGER4 P35408 1/20 0.41
PTGER2 P43116 1/20 0.41
GAA P10253 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23214481 1.00 CA1 (0.44) CA1CA2CA12CA9CA14
SCHEMBL15954162 1.00 CA1 (0.44) CA1CA2CA12CA9CA14
SCHEMBL31734452 1.00 CA1 (0.44) CA1CA2CA12CA9CA14
SCHEMBL23214542 0.81 KDM4E (0.41) ALDH1A1MAPTLMNATP53KMT2A
SCHEMBL23214541 0.81 KDM4E (0.41) ALDH1A1MAPTLMNATP53KMT2A
SCHEMBL23214544 0.81 KDM4E (0.41) ALDH1A1MAPTLMNATP53KMT2A
SCHEMBL19413995 0.80 ACACB (0.56) CA1CA2CA12CA9CA14
SCHEMBL14966445 0.80 ACACB (0.56) CA1CA2CA12CA9CA14
SCHEMBL1765715 0.80 CA1 (0.53) CA1CA2CA12CA9CA14
SCHEMBL23224262 0.79 PTGER4 (0.46) CA1CA2CA12CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4692085-A2 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS Nxera Pharma UK Limited (GB) 2026-02-11 EP disclosed
US-20260015314-A1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS NXERA PHARMA UK LTD (GB) 2026-01-15 US disclosed
EP-4041388-B1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS NXERA PHARMA UK LTD (GB) 2025-11-26 EP disclosed
US-12391641-B2 Prostaglandin EP4 receptor antagonist compounds Nxera Pharma UK Limitied (GB) 2025-08-19 US disclosed
US-20220411364-A1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS NXERA PHARMA UK LIMITED (GB) 2022-12-29 US disclosed
EP-4041388-A1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS Heptares Therapeutics Limited (GB) 2022-08-17 EP disclosed
WO-2021069927-A1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS HEPTARES THERAPEUTICS LIMITED (GB) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391641-B2 Prostaglandin EP4 receptor antagonist compounds PTGER1, PTGER4, PTGER2 CA1 4414/4885CA2 3516/4885CA12 4825/4885
US-20260015314-A1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS PTGER4, PTGER1, PTGER3 CA1 1219/4885CA2 2262/4885CA12 2959/4885
US-20220411364-A1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS PTGER1, PTGER4, PTGER2 CA1 4414/4885CA2 3516/4885CA12 4825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.